贝伐珠单抗靶向治疗卵巢癌的效果分析

Effect analysis of bevacizumab in targeted treatment of ovarian cancer

目的探讨卵巢癌采用贝伐珠单抗靶向治疗的效果。方法选取77例卵巢癌患者为研究对象,根据随机数字表法分为对照组(38例)和研究组(39例)。对照组采用常规化疗,研究组在对照组基础上采用贝伐珠单抗靶向治疗,比较两组的治疗效果、肿瘤标志物水平及不良反应发生情况。结果治疗后,研究组总有效率高于对照组(P<0.05)。治疗前,两组糖类抗原125(CA125),糖类抗原199(CA199)及癌胚抗原(CEA)水平比较,差异均无统计学意义(P>0.05);治疗后,研究组CA125、CA199、CEA水平均低于对照组(P<0.05)。研究组不良反应发生率低于对照组(P<0.05)。结论卵巢癌患者采用贝伐珠单抗靶向治疗效果较好,可降低患者的CA125、CA199、CEA肿瘤标志物水平,减少不良反应发生率,值得临床推广与应用。

Objective To investigate the efficacy of bevacizumab targeted therapy for ovarian cancer.Methods A total of 77 patients with ovarian cancer were selected and divided into control group(n=38)and study group(n=39)according to random number table method.The control group received conventional chemotherapy,and the study group received bevacizumab targeted therapy on the basis of the control group.The therapeutic effect,tumor marker level and incidence of adverse reactions were compared between the two groups.Results After treatment,the total effective rate of the study group was higher than that of the control group(P<0.05).Before treatment,there were no significant differences in carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199)and carcinoembryonic antigen(CEA)levels between the two groups(P>0.05).After treatment,CA125,CA199 and CEA levels in the study group were lower than those in the control group(P<0.05).The incidence of adverse reactions in the study group was lower than that in the control group(P<0.05).Conclusion Targeted therapy with bevacizumab for ovarian cancer has good effect,can reduce the levels of CA125,CA199 and CEA tumor markers in patients and reduce the incidence of adverse reactions,which is worthy of clinical promotion and application.